PT-141 (Bremelanotide) Pediatric Dosing: What Clinicians and Parents Must Know

The Short Answer: No Approved Pediatric Dose Exists

Bremelanotide has no established dosing for children under age 12. The FDA approved Vyleesi on June 21, 2019 exclusively for premenopausal adult women diagnosed with acquired, generalized hypoactive sexual desire disorder (HSDD). The drug's prescribing information contains no weight-based or age-adjusted dosing table for pediatric patients, and Palatin Technologies has not submitted a pediatric study plan under the Pediatric Research Equity Act (PREA) for this indication.

The approved adult dose is a single 1.75 mg subcutaneous injection administered at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than one dose per calendar day [1]. That number, 1.75 mg, was derived from adult pharmacokinetic studies in women aged 18 and older. Extrapolating it to a 20-to-30 kg child using allometric scaling would require formal pediatric PK trials that do not exist. No such trials are registered on ClinicalTrials.gov as of the date of this review.

Clinicians who receive requests to prescribe bremelanotide to a child under 12 should document refusal in the medical record, explain the absence of safety data, and refer the family to a board-certified pediatric endocrinologist or child psychiatrist as appropriate.

FDA Approval History and What the Label Actually Says

The FDA Center for Drug Evaluation and Research (CDER) approved bremelanotide following two key Phase 3 RECONNECT trials published in Obstetrics and Gynecology in 2019 [2]. Both trials enrolled premenopausal women between ages 18 and 55 with a DSM-5 diagnosis of HSDD. The combined enrollment was approximately 1,247 women across RECONNECT Study 1 and Study 2. Mean age at enrollment was 38.4 years. No participant under 18 was enrolled, and the trials included no sub-analysis relevant to pediatric physiology.

The FDA-approved prescribing information (USPI) for Vyleesi states under Section 8.4 (Pediatric Use): "The safety and effectiveness of VYLEESI in pediatric patients have not been established." [1] This language is unambiguous. It means no dose, no titration schedule, and no monitoring interval can be derived from the existing evidence base.

Under PREA (21 U.S.C. 355c), sponsors of new drug applications must submit pediatric study plans when the drug may offer a meaningful benefit for pediatric patients. The FDA waived this requirement for bremelanotide because HSDD as defined in the DSM-5 is not a condition that occurs in children under 12, who have not completed sexual maturation [3]. The waiver itself reinforces that pediatric use is not only unapproved but biologically inapplicable to the drug's indication.

The FDA's Drug Safety Communications database contains no post-marketing pediatric case reports for bremelanotide as of this writing, consistent with the drug's narrow approved use [4].

Mechanism of Action and Why Pediatric Physiology Adds Extra Risk

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist with activity at MC1R, MC3R, and MC4R [5]. Its CNS effects, particularly through MC4R signaling in the hypothalamus and limbic system, modulate sexual desire pathways that are not fully developed in prepubertal children.

The hypothalamic-pituitary-gonadal (HPG) axis in children under 12 is deliberately suppressed by central inhibitory signals until the onset of puberty. Introducing an MC4R agonist into this system is not a neutral act. Animal studies conducted during bremelanotide's development showed dose-dependent darkening of skin (flushing) via MC1R activation and increases in blood pressure averaging 6 mmHg systolic in adult subjects [1]. In a developing cardiovascular system with lower baseline vascular tone, those effects could carry a different risk profile entirely.

The drug also carries a known risk of transient hypertension. The USPI states that bremelanotide should not be used in patients with known cardiovascular disease or uncontrolled hypertension [1]. Congenital cardiac conditions are more prevalent in the pediatric population than in the adult RECONNECT trial participants, adding a second layer of concern. Nausea occurred in 40% of adult trial participants receiving the active drug versus 1% of placebo recipients [2]. Weight-based extrapolation of that adverse event rate to a 25 kg child provides no meaningful safety estimate.

RECONNECT Trial Data: Adults Only, No Downward Extrapolation Possible

The RECONNECT trials represent the totality of key Phase 3 evidence for bremelanotide. In the combined analysis, women receiving 1.75 mg bremelanotide showed statistically significant improvement on the Female Sexual Function Index desire domain and on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 compared with placebo (P<0.001 for both co-primary endpoints) [2]. Flushing was reported by 40% of active-arm participants. Nausea was the second most common adverse event at 40%.

These effect sizes were measured in adult premenopausal women with an intact and active HPG axis. The pharmacokinetic parameters used to set the 1.75 mg dose, including a peak plasma concentration (Cmax) of approximately 2.9 ng/mL and an AUC of roughly 14.3 ng·h/mL, were derived from adult body-composition profiles [1]. Children under 12 have different volume of distribution, protein binding, and hepatic metabolic capacity. Cytochrome P450 enzyme maturation is not complete until approximately age 6 to 10 for CYP3A4 and later for other isoforms relevant to peptide catabolism [6]. Any dose extrapolation would therefore be scientifically unsound.

The FDA's guidance document on general principles of pediatric dose selection explicitly states that adult PK/PD data cannot be used to derive pediatric doses without bridging studies demonstrating comparable exposure-response relationships [7]. No such bridging study exists for bremelanotide.

Legal and Ethical Dimensions of Off-Label Pediatric Prescribing

Off-label prescribing is legal in the United States. Physicians may prescribe approved drugs for unapproved uses, ages, or doses when clinical judgment supports the decision. However, off-label use carries heightened ethical obligations when the patient population is pediatric, because children cannot provide informed consent and because developmental risk is harder to characterize [8].

The American Academy of Pediatrics policy statement on off-label drug use in children (2014, reaffirmed 2021) states: "The pediatric patient should not be denied appropriate off-label therapy when the benefits outweigh the risks and there is no reasonable alternative." [8] The critical phrase is "no reasonable alternative." For a child under 12 presenting with any symptom that a clinician might consider treating with bremelanotide, such as a neurologically-based behavior concern or a hypothalamic disorder, there are evidence-based pediatric alternatives with established dosing and safety profiles.

Prescribing bremelanotide to a child under 12 could also trigger a mandatory adverse event report under FDA MedWatch (Form FDA 3500A), which is required for serious adverse events associated with off-label use in a vulnerable population [4]. Liability exposure for the prescribing clinician would be substantial.

The HealthRX clinical team uses the following three-question framework before any consideration of off-label prescribing in pediatric patients:

1. Is there a published pediatric PK or safety study for this compound in the target age range? For bremelanotide, the answer is no.
2. Does a recognized pediatric subspecialty guideline endorse off-label use in this context? For bremelanotide, no such guideline exists.
3. Has the family provided documented informed consent that specifically names the absence of pediatric trial data? If the first two answers are no, consent cannot ethically authorize proceeding.

All three criteria must be met before any off-label pediatric prescribing discussion advances beyond the chart note.

What Conditions Might Prompt This Question, and the Right Referral Path

Parents or caregivers sometimes search for PT-141 in a pediatric context after encountering the drug in online wellness communities, where it is marketed with unsubstantiated claims about mood, motivation, and social engagement. Some of these claims loosely parallel symptoms seen in autism spectrum disorder, ADHD, or hypothalamic dysfunction in children, leading families to ask clinicians about it.

Bremelanotide is not studied or approved for any of those conditions in any age group. The melanocortin system does play a role in energy balance and appetitive behavior more broadly [9], and MC4R variants are associated with monogenic obesity in children [10]. But pharmaceutical modulation of that system in a child under 12, using a drug optimized for adult sexual desire physiology, is not supported by any evidence pathway.

Appropriate referral destinations include:

• Pediatric endocrinology for MC4R-related obesity or hypothalamic disorders
• Developmental-behavioral pediatrics for ASD, ADHD, or related presentations
• Child and adolescent psychiatry for any HSDD-adjacent behavioral concern in an adolescent

Each of these specialties has access to drugs with established pediatric dosing, published safety data, and guideline support from organizations such as the American Academy of Pediatrics and the Pediatric Endocrine Society [11].

Compounded PT-141 and the Pediatric Safety Risk

A secondary concern involves compounded bremelanotide. Since Vyleesi's approval, compounding pharmacies have produced PT-141 in various concentrations, often as lyophilized powder for reconstitution. These products are not FDA-approved and do not carry the quality controls of the approved formulation [12].

For adult patients, compounded PT-141 already introduces uncertainty about potency and sterility. For a child under 12, the risk compounds. Variable concentration in a compounded vial means that even if a clinician attempted a weight-based dose calculation using allometric scaling from the 1.75 mg adult dose, the actual delivered dose would be unpredictable. The FDA's guidance on compounded drug products states that compounding for a specific patient requires a valid prescription based on a patient-specific clinical need [12]. No such clinical need has been established for bremelanotide in a child under 12.

The FDA has issued multiple warning letters to compounding pharmacies producing peptide drugs without adequate sterility testing [13]. Clinicians who recommend or prescribe compounded PT-141 for any patient, adult or pediatric, should verify the pharmacy's 503A or 503B registration status and request a certificate of analysis for each lot.

Monitoring Considerations If a Future Pediatric Indication Were Ever Studied

No pediatric indication is under active development for bremelanotide. This section is included for completeness, to address what monitoring would theoretically require if a properly designed pediatric trial were ever conducted.

Any pediatric study of a melanocortin agonist would need to monitor growth velocity, Tanner staging progression, blood pressure at each visit, hepatic function panels given peptide metabolic pathways, and the integrity of the HPG axis via LH, FSH, and age-appropriate sex hormone levels [6]. Skin pigmentation changes from MC1R activity would require dermatologic baseline photography. Cardiovascular monitoring would need to include ambulatory blood pressure recording given the 6 mmHg transient hypertension seen in adult trials [1]. These requirements reflect the FDA's Guidance for Industry on Studies in Support of Special Populations: Pediatrics, which outlines the minimum data package required before any pediatric dose can be labeled [7].

No such data package exists for bremelanotide. The absence is not a gap waiting to be filled by clinical intuition. It is a regulatory and scientific boundary.

Practical Guidance for Clinicians Receiving These Requests

Clinicians in telehealth or direct-care settings may encounter requests for bremelanotide for patients under 12 through several channels: a caregiver's online research, a wellness influencer's recommendation, or a misunderstanding of the drug's mechanism. The correct clinical response is the same regardless of the channel.

Document the request in the chart. Explain that no approved dose exists for this age group, that no pediatric safety data are available, and that prescribing would constitute off-label use with no evidentiary support. Provide a referral to a pediatric subspecialist matched to the presenting concern. File an FDA MedWatch report if the patient has already received the drug from another source [4].

The prescribing information for Vyleesi, available on FDA's accessdata portal, is the definitive document for any clinical or regulatory dispute about the drug's approved use [1]. Section 8.4 of that label is the controlling text. It contains 14 words that settle the question entirely: "The safety and effectiveness of VYLEESI in pediatric patients have not been established."